NASDAQ · CELZ
Healthcare · Biotechnology
$0.89
Down-$0.03 (-3.22%)
Updated Oct 9, 2026, 12:21 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CELZ
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
CELZ closed at $0.89 after 20 trading sessions, down 6.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $0.91 | $0.91 | $0.8801 | $0.889 | 52.22K |
| Oct 6, 2026 | $0.90 | $0.9175 | $0.89 | $0.9004 | 70.8K |
| Oct 5, 2026 | $0.96 | $0.96 | $0.92 | $0.92 | 75.37K |
| Oct 2, 2026 | $0.94 | $0.97 | $0.915 | $0.9464 | 89.49K |
| Oct 1, 2026 | $0.93 | $0.97 | $0.93 | $0.9417 | 208.31K |
| Sep 30, 2026 | $0.93 | $0.98 | $0.882 | $0.9346 | 99.36K |
| Sep 29, 2026 | $1.00 | $1.0108 | $0.91 | $0.9652 | 238.72K |
| Sep 28, 2026 | $1.00 | $1.04 | $0.98 | $1.01 | 217.09K |
| Sep 25, 2026 | $0.9902 | $1.05 | $0.942 | $1.03 | 323.68K |
| Sep 24, 2026 | $0.9482 | $0.99 | $0.92 | $0.97 | 200.75K |
| Sep 23, 2026 | $0.8908 | $1.00 | $0.8908 | $0.9738 | 366.93K |
| Sep 22, 2026 | $0.88 | $0.96 | $0.80 | $0.94 | 1.78M |
| Sep 21, 2026 | $0.9925 | $1.04 | $0.9468 | $1.005 | 20.01M |
| Sep 18, 2026 | $0.8886 | $0.9659 | $0.8743 | $0.9659 | 172.89K |
| Sep 17, 2026 | $0.86 | $0.8967 | $0.8289 | $0.8775 | 180.34K |
| Sep 16, 2026 | $0.894 | $0.90 | $0.8213 | $0.822 | 147.76K |
| Sep 15, 2026 | $0.9168 | $0.9723 | $0.85 | $0.885 | 118.84K |
| Sep 14, 2026 | $0.9513 | $0.9728 | $0.8559 | $0.8779 | 404.25K |
| Sep 11, 2026 | $0.95 | $0.998 | $0.95 | $0.9606 | 101.16K |
| Sep 10, 2026 | $1.05 | $1.0557 | $0.9363 | $0.9502 | 320.5K |
The latest Smart Investors Daily articles mentioning CELZ.
Company
Market Activity
Research & News
CELZ research
Company profile and research snapshot.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 25, 2022 | Roth Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 25, 2026
On September 24, 2026, Creative Medical Technology Holdings, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with Creative Acquisition Corp. ("CAC"),
Benzinga · Sep 22, 2026
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose 39.21% to
Yahoo · Sep 17, 2026
New Filing Seeks Broad Protection Around Creative Medical’s Cell-Free Regenerative Platform, Including Product Composition, Functional Potency, Manufacturing Controls and Additional Therapeutic ApplicationsPHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application
Benzinga · Sep 17, 2026
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CELZ.
